Pharmanutra S.p.A. (BIT:PHN)
72.20
+1.30 (1.83%)
Sep 25, 2026, 5:35 PM CET
Pharmanutra Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 691 | 521 | 523 | 542 | 601 | 730 | |
Market Cap Growth | 76.23% | -0.23% | -3.62% | -9.76% | -17.67% | 100.53% |
Enterprise Value | 695 | 520 | 523 | 552 | 595 | 710 |
Last Close Price | 72.20 | 53.47 | 52.59 | 53.64 | 58.34 | 69.83 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 33.35 | 26.07 | 31.47 | 42.26 | 39.94 | 53.01 |
Forward PE | 25.36 | 23.47 | 25.25 | 32.36 | 38.79 | 53.54 |
PS Ratio | 4.81 | 3.95 | 4.50 | 5.39 | 7.24 | 10.71 |
PB Ratio | 9.94 | 7.32 | 8.41 | 9.97 | 11.80 | 16.19 |
P/TBV Ratio | 15.44 | 10.46 | 12.79 | 16.38 | 19.87 | 18.30 |
P/FCF Ratio | 46.02 | 31.74 | 32.32 | - | - | 47.32 |
P/OCF Ratio | 36.24 | 26.66 | 25.59 | 44.85 | 34.41 | 35.76 |
PEG Ratio | - | 4.14 | 4.14 | 4.14 | 4.14 | 2.65 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.83 | 3.94 | 4.50 | 5.49 | 7.16 | 10.41 |
EV/EBITDA Ratio | 20.57 | 16.36 | 16.93 | 21.72 | 24.56 | 36.76 |
EV/EBIT Ratio | 22.67 | 17.88 | 19.11 | 24.00 | 25.78 | 38.78 |
EV/FCF Ratio | 46.23 | 31.68 | 32.33 | - | - | 46.00 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.26 | 0.29 | 0.39 | 0.52 | 0.35 | 0.14 |
Debt / EBITDA Ratio | 0.54 | 0.64 | 0.79 | 1.10 | 0.73 | 0.33 |
Debt / FCF Ratio | 1.22 | 1.25 | 1.50 | - | - | 0.41 |
Net Debt / Equity Ratio | 0.05 | -0.14 | -0.08 | 0.05 | -0.18 | -0.61 |
Net Debt / EBITDA Ratio | 0.10 | -0.32 | -0.15 | 0.11 | -0.38 | -1.43 |
Net Debt / FCF Ratio | 0.21 | -0.61 | -0.29 | -2.50 | 1.05 | -1.79 |
Asset Turnover | 1.22 | 1.09 | 1.01 | 0.95 | 0.97 | 1.11 |
Inventory Turnover | 7.46 | 8.28 | 7.53 | 7.76 | 10.13 | 15.13 |
Quick Ratio | 1.51 | 1.86 | 1.94 | 1.70 | 1.96 | 3.08 |
Current Ratio | 2.05 | 2.35 | 2.38 | 2.12 | 2.28 | 3.32 |
Return on Equity (ROE) | 31.60% | 29.87% | 28.40% | 24.36% | 31.34% | 33.26% |
Return on Assets (ROA) | 16.19% | 14.99% | 14.88% | 13.54% | 16.82% | 18.58% |
Return on Invested Capital (ROIC) | 29.78% | 32.39% | 29.06% | 25.63% | 50.00% | 74.25% |
Return on Capital Employed (ROCE) | 35.20% | 30.90% | 30.40% | 27.20% | 31.00% | 33.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.00% | 3.84% | 3.18% | 2.37% | 2.50% | 1.89% |
FCF Yield | 2.17% | 3.15% | 3.09% | -0.21% | -1.45% | 2.11% |
Dividend Yield | 1.66% | 2.24% | 1.90% | 1.58% | 1.37% | 1.02% |
Payout Ratio | 55.39% | 47.95% | 49.20% | 60.11% | 45.53% | 47.10% |
Buyback Yield / Dilution | 0.12% | 0.16% | 0.67% | 0.05% | 0.09% | - |
Total Shareholder Return | 1.78% | 2.41% | 2.57% | 1.63% | 1.46% | 1.02% |